How Can Analytics Help Avoid the PD-L1 Chaos: 10 Years of Insights - Diaceutics
+

How Can Analytics Help Avoid the PD-L1 Chaos: 10 Years of Insights



Steve Vitale
Peter Keeling
Ryan Keeling


To date, multiple PD-L1 therapies have been launched – some with a diagnostic test in-label and some not. For those therapies that require testing, we will highlight how test adoption can be optimized.

Listen to the webinar to learn:

  • 10 years of personalized medicine evidence-based insights from Diaceutics
  • The latest in data and research on PD-L1 testing, adoptions, kits and labels
  • How to prepare for targeted therapy launches
  • Laboratory mapping and optimal lab footprints based on therapy, test and target prescribers

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports

Publications

TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications